Clinical Trial Update: Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Acalabrutinib is being studied in Phase 1/2 as a single agent or in combination therapy for B-cell non-Hodgkin lymphoma, with results posted and the study curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Non Hodgkin Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-15